Glimepiride 93479-97-1
Glimepiride is a medium-to-long acting sulfonylurea anti-diabetic drug. It is marketed as Amaryl by Sanofi-Aventis. Glimepiride is the first third-generation sulfonylurea, and is very potent.
| Systematic (IUPAC) name: |
3-ethyl-4-methyl-N-(4-[N-((1r,4r)-4-methylcyclohexylcarbamoyl)sulfamoyl]phenethyl)-2-oxo-2,5-dihydro-1H-pyrrole-1-carboxamide |
| Glimepiride CAS number: |
93479-97-1 |
| ATC code: |
A10BB12 |
| PubChem: |
3476 |
| DrugBank: |
APRD00381 |
| Formula: |
C24H34N4O5S |
| Molecular mass: |
490.617 g/mol |
| Glimepiride Assay/Purity: |
Typically NLT 98% |
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
